Clinical Trials

Pancreatic Neoplasms

NCT04233866 2026-03-02

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

176 enrolled

Pancreatic Neoplasms

NCT06998940 2026-02-20

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

94 enrolled

Pancreatic Neoplasms

NCT04115163 2026-02-11

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

67 enrolled

Phase 3 Not yet recruiting

Pancreatic Neoplasms

NCT07383922 2026-02-04

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT06958328 2026-02-02

LAP100

356 enrolled

Pancreatic Neoplasms

NCT04524702 2026-01-23

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

10 enrolled 13 charts

Pancreatic Neoplasms

NCT05026905 2026-01-20

A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer

66 enrolled

Pancreatic Neoplasms

NCT04643405 2026-01-08

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Phase 1/2 Terminated

21 enrolled

Phase 2/3 Active not recruiting

Pancreatic Neoplasms

NCT06115499 2026-01-07

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

10 enrolled

Pancreatic Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07226856 2025-12-22

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

43 enrolled

Pancreatic Neoplasms

NCT03910387 2025-12-16

Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer

23 enrolled 15 charts

Pancreatic Neoplasms

NCT06385925 2025-12-15

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Phase 1/2 Recruiting

440 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06783140 2025-12-05

PLATINUM-CAN

Phase 2/3 Recruiting

10 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04054362 2025-11-21

PINBALL

27 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

61 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT04821284 2025-11-04

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Phase 1/2 Active not recruiting

120 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT05497778 2025-10-14

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

19 enrolled

Pancreatic Neoplasms

NCT04940286 2025-10-08

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

13 enrolled

Pancreatic Neoplasms

NCT04158635 2025-08-19

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Phase 1 Recruiting

21 enrolled

Pancreatic Neoplasms

NCT06423326 2025-07-30

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

36 enrolled

GastrointestinalGenitourinaryLymphoidThoracic

Pancreatic Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT02723331 2025-07-01

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

48 enrolled 13 charts

Pancreatic Neoplasms

NCT05451043 2025-06-26

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

62 enrolled

Biliary Tract Neoplasms, Liver Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT04543071 2025-06-19

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

10 enrolled

DermatologicGastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT06483555 2025-04-16

PANGEA

Phase 1/2 Recruiting

104 enrolled

Pancreatic Neoplasms, Neoplasms, Basal Cell

NCT05776524 2025-03-25

Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer

46 enrolled

Adenocarcinoma, Pancreatic Neoplasms

NCT05841420 2025-01-29

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

98 enrolled

DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

Pancreatic Neoplasms

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

Phase 1/2 Completed

79 enrolled

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

350 enrolled

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT06398587 2024-07-19

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Withdrawn

Pancreatic Neoplasms

NCT06491472 2024-07-09

Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer

36 enrolled

Pancreatic Neoplasms

NCT05832892 2024-06-14

Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer

Phase 1/2 Unknown

41 enrolled

Phase 1 Active not recruiting

Pancreatic Neoplasms

NCT04000906 2024-05-24

Nab-PIPAC

18 enrolled

GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT05493995 2024-05-09

PAAG

66 enrolled

Phase 1/2 Not yet recruiting

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

117 enrolled

Pancreatic Neoplasms

NCT04674956 2024-04-02

A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

401 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Pancreatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT03415854 2023-12-15

NABPLAGEMD

11 enrolled

Adenocarcinoma, Pancreatic Neoplasms

NCT06017284 2023-11-24

PTCA199-5

100 enrolled

Nausea, Pancreatic Neoplasms, Vomiting

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Phase 1 Completed

139 enrolled

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT02178436 2023-11-07

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Phase 1/2 Completed

15 enrolled 13 charts

Pancreatic Neoplasms

NCT06017323 2023-10-25

ProglumidePanc

Phase 1 Withdrawn

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT06080854 2023-10-12

AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer

108 enrolled

Pancreatic Neoplasms

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

Phase 2 Unknown

140 enrolled

Pancreatic Neoplasms

NCT02333188 2023-05-31

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

Phase 1 Completed

50 enrolled